icon-folder.gif   Conference Reports for NATAP  
 
  AASLD
61th Annual Meeting of the American Association for the Study of Liver Diseases
Boston, MA, Hynes Convention Center
October 30-November 3, 2010
Back grey_arrow_rt.gif
 
 
 
Initial Antiviral Activity of the HCV NS3 Protease Inhibitor ABT-450 When Given with Low-dose Ritonavir as 3-Day Monotherapy: Preliminary Results of Study M11-602 in Genotype 1 (GT1) HCV-infected Treatment-naïve Subjects
 
 
  Reported by Jules Levin
61st Annual Meeting of the American Association for the Study of Liver Diseases: The Liver Meeting - October 29-November 2, 2010 - Boston, MA
 
Eric Lawitz1, Isabelle Gaultier2, Fred Poordad3, Daniel Cohen2, Rajeev Menon2, Lois M. Larsen2, Thomas Podsadecki2, Barry Bernstein2 1Alamo Medical Research, San Antonio, TX, United States; 2Global Pharmaceutical R & D, Abbott Laboratories, Abbott Park, IL, United States; 3Hepatology, Cedars-Sinai Medical Center, Los Angeles, CA, United States